New Drug Candidate May Reduce Deficits in Parkinsonís Disease

Share

(October 31, 2016) – Researchers at University of California San Diego have employed a novel computational approach to design and create a new compound that in laboratory studies has reduced deficits and neurodegenerative symptoms that underlie Parkinson’s disease. In this study, this compound prevents the binding and accumulation of alpha-synuclein or ?-syn in neuronal membranes, now considered a hallmark of Parkinson’s disease and a related disorder called dementia with Lewy bodies. Read more

Click for a printer friendly version

Back to top